SUMMARY Within six hours of suspected acute myocardial infarction, 791 patients entered a randomised double blind study of combined intravenous and oral tocainide for the prophylaxis of primary ventricular fibrillation. Acute myocardial infarction was confirmed in 559 patients, of whom 278 had received tocainide. The study was terminated on the basis of a sequential statistical analysis which showed that in these patients tocainide was unlikely to reduce the incidence of primary ventricular fibrillation by as much as 50%, primary ventricular fibrillation having occurred in 4% of the tocainide and 2% of the placebo patients. Significantly fewer tocainide treated patients were withdrawn for other serious ventricular arrhythmias. Mortality (1% in the tocainide group and 2% in the placebo group) was low with no statistically significant differences between the active and placebo groups. Unwanted effects of treatment were infrequent and rarely troublesome both in patients with and without acute myocardial infarction.
Lignocaine,' 2 procainamide,3 quinidine,4 mexiletine,5 and tocainide67 when given prophylactically can reduce ventricular arrhythmias during acute myocardial infarction. Of these, however, only lignocainel has been shown satisfactorily to reduce the incidence of primary ventricular fibrillation-a result obtained using a high intravenous dose which was associated with frequent unwanted effects. The failure of the other drugs to achieve a reduction of ventricular fibrillation might have been because of drug inefficacy but often the numbers of patients investigated were inadequate to observe a positive effect.
Primary ventricular fibrillation, an early complication of acute myocardial infarction, decreases in incidence exponentially from the onset of symptoms. Effective prophylaxis of this arrhythmia requires rapid attainment of "therapeutic" plasma drug levels. Oral drug administration, while convenient, is unlikely to meet this demand as gastrointestinal absorption is delayed in patients who have sustained acute myocardial infarction, particularly if they have received narcotic analgesia.8 Erratic absorption and local injection site problems are common with Accepted for publication 1 March 1983 intramuscular drug administration. A combination schedule of intravenous loading and subsequent oral maintenance administration could theoretically provide rapid achievement of stable plasma levels with relative simplicity.
Tocainide, a structural analogue of lignocaine with class I antiarrhythmic actions,9 has been shown to be as effective as lignocaine in suppressing ventricular arrhythmias during acute myocardial infarction'0 but in contrast to lignocaine it has high oral bioavailability and a long half life."l Its lignocaine-like electrophysiological properties and the availability of intravenous and oral formulations prompted this study of its value for the prophylaxis of primary ventricular fibrillation in the acute phase of myocardial infarction.
Patients were excluded from the trial on the following grounds:
(1) Significant left ventricular failure defined as a combination of tachycardia, third heart sound, and dyspnoea with one of the following: basal post-tussive crepitations, radiographic pulmonary oedema, or radiographic pulmonary venous congestion-or as defined by the attending physician. (2) Arrhythmias requiring specific treatment including ventricular tachycardia, ventricular fibrillation, or other arrhythmias, at the discretion of the attending physician. (3) Cardiogenic shock (systolic blood pressure less than 90 mmHg plus vasoconstriction and poor peripheral perfusion). (4) Prior administration of an antiarrhythmic drug (including beta adrenoceptor blocking drugs). (5) Second or third degree heart block. (6) Sinus bradycardia with a heart rate of less than 60 beats/minute. (7) Known hepatic or renal disease. The remaining patients comprised the study population and were allocated on a randomised double blind basis to receive either tocainide or an identical inert placebo. Informed consent was not consistently sought from patients included in this study as it was considered not always appropriate to discuss the concept of ventricular fibrillation prophylaxis at a time when rest, sedation, relief of pain, and reassurance are important.
Patients treated with tocainide received 500 mg tocainide hydrochloride in 50 ml of 0.90/o saline intravenously over 30 minutes followed immediately by a 600 mg oral loading dose. Placebo treated patients received an infusion containing 0-90/o saline and an identical placebo tablet. The timing of subsequent oral maintenance therapy was dependent upon the patient's coronary care unit admission time to permit standardised twice daily drug administration at 0800 hours and 2000 hours. Oral treatment was continued for 48 hours after admission to the trial.
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In the first 20 patients in each participating centre, a venous blood sample was taken two hours after the oral loading dose of study medication for estimation of plasma tocainide levels.
Electrocardiograms were monitored in the conventional manner. Drugs for the management of pain and cardiac failure were given as required but no routine use of antiarrhythmic drugs or beta adrenoreceptor blocking drugs was permitted. The diagnosis of acute myocardial infarction in the study population was confirmed by the presence of two or more of the following: typical history; characteristic electrocardiographic abnormalities (new Q waves and/or sequential ST and T wave changes); and an increase in serum enzyme concentrations to at least twice the upper limit of normal for that particular laboratory.
Patients were withdrawn from the study if: lation on tocainide treatment at the 5% level. This test had a 95% power against the alternative that the incidence of ventricular fibrillation on tocainide treatment was 50%/o of that on placebo treatment. (2) The sequential test showed no significant reduction (that is the incidence of ventricular fibrillation on tocainide treatment was greater than 50% of that on placebo treatment). (3) On periodic examination of the data the incidence of the combination of death, ventricular fibrillation, bradycardia, hypotension, left ventricular failure, asystole, second or third degree heart block was higher in the tocainide treated patients than in those receiving placebo (statistical significance required p<0-05). (4) On periodic examination of the data the incidence of any one of the following: death, ventricular tachycardia, bradycardia, hypotension, left ventricular failure, asystole, second or third degree heart block was higher in the tocainide treated pati p<0*0l Table 1 . No statistically significant or important differences were present apart from a significant (p<0-0l) maldistribution of infarct site. A small excess of placebo patients entered the study within one hour of the onset of symptoms.
ients (statistical significance required Major endpoints (Table 2) Death: During drug administration, three tocainide ie above reasons for study termina-and six placebo patients died (no significant differred within two years of recruitment ence). patient.
During the study period (48 hours from inclusion ysis of the final results was by x2 tests in the study), six tocainide and eight placebo patients ection for comparison of proportions died. Three tocainide patients who were withdrawn mparison of means. Linear logistic (one for R-on-T ventricular extrasystoles, one for ion was used for the analysis of complete heart block, and one with heart failure) subwithin strata defined by site of acute sequently died within the study period (the first as a :tion.
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Withdrawals (excluding death and primary ventricular fibrillation): Thirty-six tocainide and 51 placebo patients were withdrawn during the course of the study (Tables 2 and 3 The overall incidence of unwanted effects, both cardiac and non-cardiac, is presented in Table 4 . There were no significant differences between the treatment groups with respect to either the total number or any specific adverse event.
CHARACTERISTICS OF VENTRICULAR FIBRILLATION PATIENTS
Comparative clinical data for the 14 patients with primary ventricular fibrillation (in the absence of shock or cardiac failure) before withdrawal and the 561 545 patients without ventricular fibrillation is presented in Table 5 . Ventricular fibrillation was significantly associated with inferior infarction, older age, and shorter onset of symptoms to admission times.
The comparative clinical data for patients in the tocainide and placebo groups are presented in Table  6 . There were no significant differences though there were more inferior infarcts in the tocainide group. In view of the discrepancy in site distribution of acute myocardial infarction between treatments, a stratified analysis of ventricular fibrillation incidence by site was also carried out. This resulted in a change in the confidence limits of relative risk from 060/5*73 to 0-50/4-91, the difference in incidence of ventricular fibrillation between the treatment groups remaining non-significant.
TOCAINIDE PLASMA CONCENTRATIONS
Tocainide plasma levels for 87 group 1 and 37 group 2 patients were obtained. The mean±+SD plasma level in group 1 was 4-8+3*5 mg base/l and 6*4+2*7 in group 2 (p<0-05). Thirty-two patients (37%) in group for this and we assume that it has occurred by chance.
There was a high incidence of death (two of 28) and of cardiac events (nine of 28) in group 3 patients (protocol violators and those with inadequate data). This phenomenon occurred both in active and placebo treated patients and, while our inclusion criteria were primarily designed to prevent inappropriate administration of tocainide, the figures indicate that patients who should be excluded from such investigations are themselves a high risk group. Similar findings have been noted in other studies.5 6 This study is one of very few which has arrived at a firm conclusion regarding the efficacy of a drug for ventricular fibrillation prophylaxis. Further investigations of drug prophylaxis of ventricular fibrillation are required and should employ a study design which permits a positive statistical statement ofdrug efficacy. 
